TRACON Pharmaceuticals, Inc.
(NASDAQ : TCON)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. -1.48%348.360.0%$6628.55m
BNTXBioNTech SE 3.78%340.770.0%$1134.35m
SNSSSunesis Pharmaceuticals, Inc. 2.85%10.820.7%$756.36m
NVAXNovavax, Inc. 3.19%185.0579.8%$669.74m
AMGNAmgen, Inc. -0.66%239.951.3%$495.96m
BIIBBiogen, Inc. 1.74%332.401.7%$438.74m
VRTXVertex Pharmaceuticals, Inc. -1.90%197.761.9%$406.87m
GILDGilead Sciences, Inc. -0.10%68.231.0%$400.95m
REGNRegeneron Pharmaceuticals, Inc. 0.33%576.522.7%$355.06m
ILMNIllumina, Inc. -0.38%493.863.5%$263.00m
NTLAIntellia Therapeutics, Inc. -2.55%138.242.3%$257.18m
CRSPCRISPR Therapeutics AG 1.61%122.970.6%$147.06m
EXASEXACT Sciences Corp. 1.36%109.3118.1%$125.27m
XBIOXenetic Biosciences, Inc. 22.36%4.980.0%$125.03m
SGENSeagen Inc. 0.13%153.595.8%$120.38m

Company Profile

TRACON Pharmaceuticals, Inc. engages in the development and commercialization of targeted therapies for cancer, ophthalmic, and fibrotic diseases. Its products include TRC105, an anti-endoglin antibody for the treatment of solid tumor types; TRC205 created for the treatment of fibrotic diseases; and TRC102, a small molecule that is in clinical development made for lung cancer and glioblastoma. The company was founded in October 2004 and is headquartered in San Diego, CA.